Vaccine Market
Description
Vaccine Market Summary
The global vaccine market size was estimated at USD 72.75 billion in 2025 and is projected to reach USD 115.77 billion by 2033, growing at a CAGR of 5.78% from 2026 to 2033. The market is driven by the increasing investment in R&D and the rising focus of sponsors & investigators on reducing research costs.
Moreover, the increasing adoption of outsourcing laboratory services by pharmaceutical & biotechnology companies and other end users to reduce the overall cost of research activities further supports the market growth over the forecast period. The global vaccine industry is positioned as a strategic component of preventive healthcare systems and is primarily driven by public immunization programs, outbreak preparedness, and routine disease prevention initiatives across regions. Vaccines are integrated into national healthcare budgets and long-term public health planning due to their role in reducing disease burden and downstream treatment costs. According to the World Health Organization, immunization prevents an estimated 2-3 million deaths every year worldwide by protecting against vaccine-preventable diseases such as measles, diphtheria, tetanus, pertussis, and influenza. In April 2024, the WHO published a comprehensive analysis in The Lancet reporting that global immunization programs have prevented approximately 154 million deaths over the past 50 years, reinforcing vaccination as a central public health investment. In April 2025, the World Health Organization marked World Immunization Week with a focus on closing immunization gaps, strengthening immunization delivery systems, and expanding vaccine coverage across the life course, reflecting continued global policy prioritization of immunization as a core public health intervention.
Market growth is supported by the continued prevalence of infectious diseases, expansion of adult and geriatric immunization programs, and recovery of routine vaccination coverage following pandemic-related disruptions. According to the World Health Organization Global Tuberculosis Report 2024, an estimated 10.8 million people developed tuberculosis globally in 2023, with the highest burden concentrated in regions such as Southeast Asia and Africa, sustaining demand for preventive and control strategies in high-burden markets. In April 2024, the World Health Organization Global Hepatitis Report estimated that approximately 254 million people were living with chronic hepatitis B and 50 million with chronic hepatitis C worldwide, with more than 1 million new viral hepatitis infections occurring each year, underscoring the continued public health burden of hepatitis globally. In May 2025, the U.S. Food and Drug Administration approved Moderna’s next-generation COVID-19 vaccine, mNEXSPIKE, for older adults aged 65 years and above and for individuals aged 12-64 years with underlying medical conditions, indicating continued regulatory support for vaccine adoption among high-risk populations.
The market is increasingly shaped by shifts in technology platforms, product portfolios, and manufacturing strategies, reflecting a transition toward broader disease coverage and long-term supply resilience. Platform-based development approaches, particularly mRNA technologies, have enabled faster design cycles, greater flexibility in antigen selection, and the development of combination vaccines, supporting portfolio expansion beyond single-disease products. These advancements are contributing to increased focus on respiratory indications and multi-pathogen prevention strategies, particularly within adult and elderly populations. In September 2022, Pfizer and BioNTech initiated Phase III clinical trials for an mRNA-based influenza vaccine, marking the extension of mRNA platforms beyond COVID-19 applications. In May 2025, the World Health Organization reported that its mRNA Technology Transfer Programme had expanded to 15 global partners, supporting the decentralization of vaccine manufacturing and the development of regional production capacity. In parallel, expanding adult immunization frameworks and broader regulatory recommendations are increasing the addressable market for vaccines across age groups, indicating that market evolution is being driven by public-sector priorities, platform diversification, and demographic shifts rather than short-term demand fluctuations.
Global Vaccine Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global vaccine market report based on indication, type, route of administration, age group, distribution channel, and region:
The global vaccine market size was estimated at USD 72.75 billion in 2025 and is projected to reach USD 115.77 billion by 2033, growing at a CAGR of 5.78% from 2026 to 2033. The market is driven by the increasing investment in R&D and the rising focus of sponsors & investigators on reducing research costs.
Moreover, the increasing adoption of outsourcing laboratory services by pharmaceutical & biotechnology companies and other end users to reduce the overall cost of research activities further supports the market growth over the forecast period. The global vaccine industry is positioned as a strategic component of preventive healthcare systems and is primarily driven by public immunization programs, outbreak preparedness, and routine disease prevention initiatives across regions. Vaccines are integrated into national healthcare budgets and long-term public health planning due to their role in reducing disease burden and downstream treatment costs. According to the World Health Organization, immunization prevents an estimated 2-3 million deaths every year worldwide by protecting against vaccine-preventable diseases such as measles, diphtheria, tetanus, pertussis, and influenza. In April 2024, the WHO published a comprehensive analysis in The Lancet reporting that global immunization programs have prevented approximately 154 million deaths over the past 50 years, reinforcing vaccination as a central public health investment. In April 2025, the World Health Organization marked World Immunization Week with a focus on closing immunization gaps, strengthening immunization delivery systems, and expanding vaccine coverage across the life course, reflecting continued global policy prioritization of immunization as a core public health intervention.
Market growth is supported by the continued prevalence of infectious diseases, expansion of adult and geriatric immunization programs, and recovery of routine vaccination coverage following pandemic-related disruptions. According to the World Health Organization Global Tuberculosis Report 2024, an estimated 10.8 million people developed tuberculosis globally in 2023, with the highest burden concentrated in regions such as Southeast Asia and Africa, sustaining demand for preventive and control strategies in high-burden markets. In April 2024, the World Health Organization Global Hepatitis Report estimated that approximately 254 million people were living with chronic hepatitis B and 50 million with chronic hepatitis C worldwide, with more than 1 million new viral hepatitis infections occurring each year, underscoring the continued public health burden of hepatitis globally. In May 2025, the U.S. Food and Drug Administration approved Moderna’s next-generation COVID-19 vaccine, mNEXSPIKE, for older adults aged 65 years and above and for individuals aged 12-64 years with underlying medical conditions, indicating continued regulatory support for vaccine adoption among high-risk populations.
The market is increasingly shaped by shifts in technology platforms, product portfolios, and manufacturing strategies, reflecting a transition toward broader disease coverage and long-term supply resilience. Platform-based development approaches, particularly mRNA technologies, have enabled faster design cycles, greater flexibility in antigen selection, and the development of combination vaccines, supporting portfolio expansion beyond single-disease products. These advancements are contributing to increased focus on respiratory indications and multi-pathogen prevention strategies, particularly within adult and elderly populations. In September 2022, Pfizer and BioNTech initiated Phase III clinical trials for an mRNA-based influenza vaccine, marking the extension of mRNA platforms beyond COVID-19 applications. In May 2025, the World Health Organization reported that its mRNA Technology Transfer Programme had expanded to 15 global partners, supporting the decentralization of vaccine manufacturing and the development of regional production capacity. In parallel, expanding adult immunization frameworks and broader regulatory recommendations are increasing the addressable market for vaccines across age groups, indicating that market evolution is being driven by public-sector priorities, platform diversification, and demographic shifts rather than short-term demand fluctuations.
Global Vaccine Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global vaccine market report based on indication, type, route of administration, age group, distribution channel, and region:
- Indication Outlook (Revenue, USD Million, 2021 - 2033)
- Viral Vaccines
- Hepatitis
- Pediatric (Children)
- Adult
- Influenza
- Pediatric (Children)
- Adult
- HPV
- Pediatric (Children)
- Adult
- MMR
- Pediatric (Children)
- Adult
- Rotavirus
- Pediatric (Children)
- Adult
- Herpes Zoster
- Pediatric (Children)
- Adult
- Japanese Encephalitis
- Pediatric (Children)
- Adult
- RSV
- Pediatric (Children)
- Adult
- Others
- Pediatric (Children)
- Adult
- Bacterial Vaccines
- Meningococcal Diseases
- Pediatric (Children)
- Adult
- Pneumococcal diseases
- Pediatric (Children)
- Adult
- DPT
- Pediatric (Children)
- Adult
- Others
- Pediatric (Children)
- Adult
- Cancer Vaccines
- Pediatric (Children)
- Adult
- Allergy Vaccines
- Pediatric (Children)
- Adult
- Other
- Pediatric (Children)
- Adult
- Type Outlook (Revenue, USD Million, 2021 - 2033)
- Subunit Vaccines
- Recombinant Vaccines
- Conjugate Vaccines
- Toxoid Vaccines
- Inactivated
- Live Attenuated
- mRNA Vaccines
- Viral Vector Vaccines
- Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
- Oral
- Parenteral
- Nasal
- Age Group Outlook (Revenue, USD Million, 2021 - 2033)
- Pediatric
- Adult
- Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
- Hospital & Retail Pharmacies
- Government Suppliers
- Others
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
150 Pages
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Research Methodology
- 1.2.1. Information Procurement
- 1.3. Information or Data Analysis
- 1.4. Methodology
- 1.5. Research Scope and Assumptions
- 1.6. Market Formulation & Validation
- 1.7. List of Data Sources
- Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Competitive Insights
- Chapter 3. Middle East Cold Storage Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
- 3.2.3. Industry Challenge
- 3.3. Middle East Cold Storage Market Analysis Tools
- 3.3.1. Industry Analysis - Porter’s
- 3.3.1.1. Bargaining power of the suppliers
- 3.3.1.2. Bargaining power of the buyers
- 3.3.1.3. Threats of substitution
- 3.3.1.4. Threats from new entrants
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Economic and social landscape
- 3.3.2.3. Technological landscape
- Chapter 4. Middle East Cold Storage Market: Type Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Middle East Cold Storage Market: Type Movement Analysis, USD Million, 2025 & 2033
- 4.3. Facilities/Services
- 4.3.1. Facilities/Services Market Revenue Estimates and Forecasts, 2021 - 2033(USD Million)
- 4.3.2. Refrigerated warehouse
- 4.3.2.1. Refrigerated warehouse Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.3.2.2. Private & Semi-Private
- 4.3.2.2.1. Private & Semi-Private Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.3.2.3. Public
- 4.3.2.3.1. Public Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.3.3. Cold room
- 4.3.3.1. Cold room Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.4. Equipment
- 4.4.1. Equipment Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.4.2. Blast freezer
- 4.4.2.1. Blast freezer Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.4.3. Walk-in cooler and freezer
- 4.4.3.1. Walk-in cooler and freezer Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.4.4. Deep freezer
- 4.4.4.1. Deep freezer Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.4.5. Others
- 4.4.5.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 5. Middle East Cold Storage Market: Temperature Range Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. Middle East Cold Storage Market: Temperature Range Movement Analysis, USD Million, 2025 & 2033
- 5.3. Chilled (0°C to 15°C)
- 5.3.1. Chilled (0°C to 15°C) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.4. Frozen (-18°C to -25°C)
- 5.4.1. Frozen (-18°C to -25°C) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.5. Deep-frozen (Below -25°C)
- 5.5.1. Deep-frozen (Below -25°C) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 6. Middle East Cold Storage Market: Application Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. Middle East Cold Storage Market: Application Movement Analysis, USD Million, 2025 & 2033
- 6.3. Food & Beverages
- 6.3.1. Food & Beverages Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.3.2. Fruits & Vegetables
- 6.3.2.1. Fruits & Vegetables Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.3.3. Fruit Pulp & Concentrates
- 6.3.3.1. Fruit Pulp & Concentrates Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.3.4. Dairy products
- 6.3.4.1. Dairy products Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.3.4.2. Milk
- 6.3.4.2.1. Milk Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.3.4.3. Butter
- 6.3.4.3.1. Butter Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.3.4.4. Cheese
- 6.3.4.4.1. Cheese Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.3.4.5. Ice Cream
- 6.3.4.5.1. Ice Cream Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.3.4.6. Others
- 6.3.4.6.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.3.5. Fish, meat, and Seafood
- 6.3.5.1. Fish, meat, and Seafood Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.3.6. Processed Food
- 6.3.6.1. Processed Food Market Revenue Estimates and Forecasts, 2021 - 2033(USD Million)
- 6.3.7. Bakery & Confectionary
- 6.3.7.1. Bakery & Confectionary Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.3.8. Others
- 6.3.8.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.4. Pharmaceuticals
- 6.4.1. Pharmaceuticals Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.4.2. Vaccines
- 6.4.2.1. Vaccines Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.4.3. Blood Banking
- 6.4.3.1. Blood Banking Market Revenue Estimates and Forecasts, 2021 - 2033(USD Million)
- 6.4.4. Others
- 6.4.4.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033(USD Million)
- 6.5. Others
- 6.5.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033(USD Million)
- Chapter 7. Middle East Cold Storage Market: Country Estimates & Trend Analysis
- 7.1. Middle East Cold Storage Market Share, By Country, 2025 & 2033, USD Million
- 7.2. UAE
- 7.2.1. UAE Cold Storage Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3. KSA
- 7.3.1. KSA Cold Storage Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4. Turkey
- 7.4.1. Turkey Cold Storage Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5. Qatar
- 7.5.1. Qatar Cold Storage Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 8. Competitive Landscape
- 8.1. Company Categorization
- 8.2. Company Market Positioning
- 8.3. Company Heat Map Analysis
- 8.4. Company Profiles/Listing
- 8.4.1. Global Star Group
- 8.4.1.1. Participant’s Overview
- 8.4.1.2. Financial Performance
- 8.4.1.3. Product Benchmarking
- 8.4.1.4. Strategic Initiatives
- 8.4.2. A.P. Moller - Maersk
- 8.4.2.1. Participant’s Overview
- 8.4.2.2. Financial Performance
- 8.4.2.3. Product Benchmarking
- 8.4.2.4. Strategic Initiatives
- 8.4.3. RSG GLOBAL COLD STORE
- 8.4.3.1. Participant’s Overview
- 8.4.3.2. Financial Performance
- 8.4.3.3. Product Benchmarking
- 8.4.3.4. Strategic Initiatives
- 8.4.4. Transworld Group
- 8.4.4.1. Participant’s Overview
- 8.4.4.2. Financial Performance
- 8.4.4.3. Product Benchmarking
- 8.4.4.4. Strategic Initiatives
- 8.4.5. Al-Futtaim Logistics
- 8.4.5.1. Participant’s Overview
- 8.4.5.2. Financial Performance
- 8.4.5.3. Product Benchmarking
- 8.4.5.4. Strategic Initiatives
- 8.4.6. RSA Cold Chain
- 8.4.6.1. Participant’s Overview
- 8.4.6.2. Financial Performance
- 8.4.6.3. Product Benchmarking
- 8.4.6.4. Strategic Initiatives
- 8.4.7. Snowland Cooling Systems LLC
- 8.4.7.1. Participant’s Overview
- 8.4.7.2. Financial Performance
- 8.4.7.3. Product Benchmarking
- 8.4.7.4. Strategic Initiatives
- 8.4.8. Clarion Shipping Services L.L.C
- 8.4.8.1. Participant’s Overview
- 8.4.8.2. Financial Performance
- 8.4.8.3. Product Benchmarking
- 8.4.8.4. Strategic Initiatives
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
